Dr. Ooi Wei Seong

Medical Director
Consultant Medical Oncologist

​MRCP (UK), MB BCh BAO (Ireland)

4.png

About Dr. Ooi

Languages Spoken: English, Mandarin, Bahasa Indonesia, Bahasa Melayu, Cantonese

Department: Medical Oncology

Dr Ooi's expertise is around the area of Lung, Breast, and Colon cancers, with frequent updates on treatments for cancer at renowned medical oncology conferences worldwide multiple times a year. Management of all solid tumour types, bone health and mechanisms of bone metastases in cancer patients.

Clinical Interests & Contributions

With a special interest in breast, lung, gastrointestinal, and gynaecological cancers:

Dr Ooi has contributed to over 20 peer-reviewed publications on medical oncology, was involved in multiple investigator-initiated and pharmaceutical-led clinical trials, and frequently attends international conferences and meetings on cancer.

Dr. Ooi has also presented his research on bone health and mechanisms of bone metastases in cancer patients at these events. In addition, he enjoys giving public talks on cancer risks, screening, and treatment both locally and overseas.

Previously a Clinical Tutor at Yong Loo Lin School of Medicine at the National University of Singapore in addition to providing teachings to junior doctors, nurses, Duke-NUS students, and elective fellows.

Recipient of the Singapore Health Quality Service Award in 2011.

Qualifications

AOMS.jpeg
specialist accreditation board .jpeg
Royale College_edited.jpg
Dublin_edited.jpg

Fellow of Academy of Medicine Singapore (Medical Oncology)

Specialist Accreditation in Medical Oncology (Singapore)

Membership of Royal of College of Physicians of United Kingdom (Edinburgh), MRCP (UK)

MB BCh BAO BA (Honours)

2015

2012

2003

1999

Research & Publications

See my Research & Publications


1. Prognostic Value of Transmittance Waveform Analysis may differ for ICU and General Medical Patients. Hayden PJ, Ooi W, Collins B, Mc Carthy D, Murphy K. Postal presentation at: XVIII Congress of the International Society on Thrombosis and Haemostasis (ISTH). July 6-12, 2001. 2. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Crown J, O’Leary M, Ooi WS Oncologist. 2004;9 Suppl 2:24-32. Review. 3. Medical problems in patients with malignancy: case 3. Ulcerating cytomegalovirus bronchitis in a patient with relapsed non-Hodgkin’s lymphoma. Ooi WS, Crown JP. J Clin Oncol. 2004 Oct 1;22(19):4022-3. 4.Salvage treatment of patients with multiply-relapsed, unresectable, metastatic Germ-Cell Tumor (GCT), following failed multi-cycle, high-dose Chemotherapy (HDC): Durable remission is still possible. Morris P, Ooi W, Wroblickey P, Duffy K, Donnellan P, Ballot J, Armstrong J, Thornhill J, Crown J. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4790 5. Why do patients with metastatic breast cancer (MBC) continue to have bone destruction despite bisphosphonate (BP) use? A pathologic review. Ooi, C. Gainford, H. Kahn, M. Kalina, S. Popovic, G. Singh, M. Clemons. Poster presentation at: The Eighth and Valedictory Workshop on Bisphosphonates – From the Laboratory to the Patient. Davos, Switzerland. Mar 22-24, 2006. Clinical session, poster no.98. 6. Bisphosphonate use for metastatic breast cancer – Too much? Too little? Too late to start again? Vanhuyse M. Gainford MC, Ooi W, Dranitsaris G, Clemons M. Poster presentation at: The Eighth and Valedictory Workshop on Bisphosphonates – From the Laboratory to the Patient. Davos, Switzerland. Mar 22-24, 2006. Clinical session, poster no.108. Page 5 of 7. 7. Urinary n-telopeptide (NTX) predicts palliative pain response in metastatic breast cancer patients receiving second-line zoledronic acid. Dranitsaris, M. Clemons, W. Ooi, D. Cole. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 679. 8.Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE. J Clin Oncol, 2006 Oct 20;24(30):4895-900. Epub 2006 Sep 25. 9. Oral ibandronate provides significant palliative benefit in metastatic breast Cancer patients who have experienced bony progression or a skeletal related event (SRE) despite first-line bisphosphonate therapy. Clemons M, Dranitsaris G, Ooi WS, Yogendran G, Cole DEC. Poster presentation at: 29th Annual San Antonio Breast Cancer Symposium. Dec 14-17, 2006. Poster Session III. 10.Practices of Bone Mineral Density testing for osteoporosis in postmenopausal women following diagnosis and completion of primary treatment of breast cancer at Toronto Sunnybrook Regional Cancer Centre. Ooi WS, Hawker G, Loblaw A, Beyenne J, Pritchard K. Poster presentation at: Canadian Association of Medical Oncologists (CAMO) 2007 Annual Scientific Meeting. Apr 26, 2007.
11. Mechanisms of bone metastasis growth in patients with metastatic breast cancer: An exploratory study. W.S. Ooi, S. Popovic, M. Kalina, H.Kahn, G.Singh, M.C. Gainford, M. Clemons. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings. Vol 25, No 18S (June 20 Supplement), 2007: 1102. 12. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. O’Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O’Connor R, Clynes M, Crown J, Kennedy S. Anticancer Res. 2007 Jul-Aug;27(4B):2115-20. 13. Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertain. Nan Soon Wong, Wei Seong Ooi, Kathleen I Pritchard. J Clin Oncol 2007 Aug;25(24):3787 Page 6 of 7. 14. Practices of Bone Mineral Density testing for osteoporosis in postmenopausal women following diagnosis and completion of primary treatment of breast cancer at Toronto Sunnybrook Regional Cancer Centre. Ooi WS, Hawker G, Loblaw A, Beyenne J, Pritchard K. Poster presentation at: Canadian Oncology Winter Conference- Targeted Therapy & Chemotherapy in Oncology. Mar 6-9, 2008. 15. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Amir E, Ooi WS, Simmons C, Kahn H, Christakis M, Popovic S, Kalina M, Chesney A, Singh G, Clemons M. Clin Oncol (R Coll Radiol). 2008 Dec;20(10):763-8. Epub 2008 Sep 27 16. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer. Trinkaus M, Ooi WS, Amir E, Popovic S, Kalina M, Singh G, Gainford MC, Clemons M. Oncol Rep. 2009 May;21(5):1153-9. 17. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. Cancer. 2010 Jan 15;115(2):284-91. 18. Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis. Walsh N, Kennedy S, Larkin AM, Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I, Collins D, Ballot J, Ooi WS, Gullo G, Clynes M, Crown J, O’Driscoll L. Br J Cancer. 2010 Mar 30;102(7):1157-62. 19. A case of large B-cell intravascular lymphoma in the brain Gan LP, Ooi WS, Lee HY, Ng WH. Surg Neurol Int. 2013 Jul 26;4:99. 20. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients. Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, Madhukumar P, Ooi WS, Chay WY, Dent RA, Ang SF, Lo SK, Yap YS, Ng R, Chan A J Clin Epidemiol 2014 Jul 18;67(7):811-20. Epub 2014 Mar 18. Page 7 of 7. 21. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Lim WK, Ong CK, Tan J, Thike AA, Ng CC, Rajasegaran V, Myint SS, Nagarajan S, Nasir ND, McPherson JR, Cutcutache I, Poore G, Tay ST, Ooi WS, Tan VK, Hartman M, Ong KW, Tan BK, Rozen SG, Tan PH, Tan P, Teh BT. Nat Genet. 2014 Aug;46(8):877-80. 22. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, Lee JA, Fan G, Tan YP, Yong WS, Madhukumar P, Loo SK, Ang SF, Wong M, Chay WY, Ooi WS, Dent RA, Yap YS, Ng R, Chan A. Ann Oncol. 2015 Jul;26(7):1446-5.